Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $845,529 - $1.46 Million
5,900 Added 236.0%
8,400 $2.04 Million
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $1.03 Million - $1.39 Million
-7,000 Reduced 73.68%
2,500 $373,000
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $1.44 Million - $1.87 Million
9,500 New
9,500 $1.82 Million
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $462,525 - $530,125
2,500 New
2,500 $474,000
Q4 2022

Feb 10, 2023

SELL
$185.53 - $241.31 $18,553 - $24,131
-100 Reduced 50.0%
100 $24,000
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $13,854 - $23,200
100 Added 100.0%
200 $40,000
Q2 2022

Aug 12, 2022

SELL
$120.42 - $169.29 $469,638 - $660,231
-3,900 Reduced 97.5%
100 $15,000
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $788,516 - $1.08 Million
-6,200 Reduced 60.78%
4,000 $653,000
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $1.63 Million - $2.13 Million
10,200 New
10,200 $1.73 Million
Q3 2021

Nov 12, 2021

SELL
$169.75 - $207.73 $4.24 Million - $5.19 Million
-25,000 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$128.63 - $176.89 $2.73 Million - $3.75 Million
21,200 Added 557.89%
25,000 $4.24 Million
Q1 2021

May 14, 2021

SELL
$126.83 - $175.69 $2.37 Million - $3.29 Million
-18,700 Reduced 83.11%
3,800 $537,000
Q3 2020

Nov 13, 2020

BUY
$121.19 - $165.49 $2.46 Million - $3.36 Million
20,300 Added 922.73%
22,500 $3.28 Million
Q2 2020

Aug 14, 2020

SELL
$104.21 - $156.44 $1.34 Million - $2.02 Million
-12,900 Reduced 85.43%
2,200 $326,000
Q4 2019

Feb 13, 2020

SELL
$74.51 - $124.23 $558,825 - $931,725
-7,500 Reduced 33.19%
15,100 $1.74 Million
Q1 2019

May 15, 2019

BUY
$72.76 - $93.45 $1.64 Million - $2.11 Million
22,600 New
22,600 $2.11 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $33.8B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.